Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Hydroxychloroquine (HCQ) has been reported to be effective in lowering urinary protein in Chinese patients with IgA nephropathy (IgAN).1 2 In a randomized placebo controlled trial by Li et al. evaluating HCQ versus placebo in Asian patients with proteinuria of 0.75–3.5 g/d despite optimized renin-angiotensin-aldosterone system (RAAS) inhibitor therapy, proteinuria was reduced by 48% vs 10% in the placebo group at 6 months.3 However, there has been limited reports of the effectiveness of HCQ in other patient populations. The 2025 Kidney Disease Improving Global Outcomes (KDIGO) guidelines for IgAN indicate that HCQ can be considered for Chinese patients who are at high risk of progression despite optimal supportive care, but indicated that there is insufficient evidence for use in non-Chinese patients.4
We conducted a retrospective observational analysis of non-Chinese patients with biopsy proven IgAN on maximal conservative therapy, initiated on HCQ at a single center. The primary outcome was reduction in urine albumin to creatinine ratio (UACR) at 6 months.
The study cohort consisted of 32 non-Chinese patients initiated on HCQ during the evaluation period between January 2021 to January 2025, with a mean age of 42, 72% were female, 63% were Caucasian and 28% were South East Asian. Patients had a mean baseline eGFR of 51 ml/min/1.73m2 and a median UACR of 139 mg/mmol. At 6 months from HCQ initiation, patients had a mean decrease in UACR of 50 mg/mmol. Three patients (9%) achieved complete remission (urine ACR <30 mg/mmol), 3 patients (9%) achieved partial remission (ACR < 60 mg/mmol) and an additional 3 patients (9%) had > 50% reduction in UACR. HCQ was well tolerated with no adverse events reported.
In this single center study, HCQ was well tolerated and effective in lowering proteinuria at 6 months in 28% of non-Chinese patients. Further prospective research in diverse populations and evaluation of ethnicities that may benefit most from HCQ is warranted.
